T1 Tumor limited to the pancreas and size <2 cm T2 Tumor limited to the pancreas and size 2–4 cm T3 Tumor limited to the pancreas and size >4 cm or invading duodenum or bile duct T4 Tumor ...

Primary neuroendocrine carcinoma of the male breast is an exceptionally rare entity, with fewer than 50 cases documented in ...

While Novartis and Bayer got there first, AstraZeneca, Bristol Myers Squibb and Eli Lilly are all vying to bring their ...

The U.S. Food and Drug Administration has approved cabozantinib (Cabometyx), an oral tyrosine kinase inhibitor, for patients ...

Jennifer Chan, MD, MPH, discussed the recent FDA approval of cabozantinib in pancreatic and extrapancreatic neuroendocrine tumors.

Pancreatic cancer is on the rise in the United States, but there's another, less common type called pancreatic neuroendocrine ...

The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.

The approval came on the bases of the results from the phase 3 CABINET study. The study compared cabozantinib to a placebo in ...

Approval was based on findings from the pivotal CABINET trial showing improved PFS and response rates vs placebo.

Cabozantinib, an oral tyrosine kinase inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with previously treated advanced neuroendocrine tumors ...

Exelixis, Inc. EXEL announced that the FDA has approved the label expansion of its lead drug Cabometyx (cabozantinib). The ...

The FDA has completed its review of the investigational new drug application (IND) for PSV359, and issued a "study may proceed” letter in 1Q 2025. Site activation activities are underway, with the ...